Abstract
Objective:
Neonatal gastroesophageal reflux (GER) is primarily due to a transient motility disorder and characterized by a prevalence of weakly acid refluxes. Drug management, where necessary, must set out to reduce the number of refluxes besides correct their acidity. Prokinetics could be of assistance in this respect, though the evidence in favor of their efficacy and safety is still far from sufficient. In this randomized controlled study, the action of domperidone, a prokinetic antidopaminergic drug with little effect on the central nervous system, was evaluated in newborns with symptomatic GER.
Study Design:
Combined multichannel intraluminal impedance and pH measuring for 24 h was carried out in 13 newborns receiving 0.3 mg per kg domperidone per os at the eighth and the sixteenth hour, and 13 controls. Each newborn was compared to the control nearest in postconceptional age.
Result:
GER episodes per hour increased significantly compared to the baseline in the domperidone group (4.06±1.16 vs 2.8±1.42; P=0.001) and were shorter (16.68±4.49 vs 20.18±7.83 s; P=0.043), whereas there were no differences in the maximu proximal extent reached by the refluxes (3.37±0.45 vs 3.34±0.94 channels; P=0.894) and their pH (4.72±0.69 vs 4.60±1.17; P=0.634).
Conclusion:
This paradoxical increase in the number of GER episodes could be the expression of a domperidone-induced amplification of the motor incoordination of the neonatal gastroesophageal tract. Doubt is thus cast on the efficacy of prokinetics in this age bracket, especially in view of their adverse effects as described in the literature.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Tolia V, Wuerth A, Thomas R . Gastroesophageal reflux disease: review of presenting symptoms, evaluation, management, and outcome in infants. Dig Dis Sci 2003; 48: 1723–1729.
Nelson SP, Chen EH, Syniar GM, Christoffel KK . Prevalence of symptoms of gastroesophageal reflux during infancy. A pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 1997; 151: 569–572.
Milla P, Cucchiara S, DiLorenzo C, Rivera NM, Rudolph C, Tomomasa T . Motility disorders in childhood: Working Group Report of the first world congress of pediatric gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol Nutr 2002; 35 (Suppl 2): S187–S195.
Omari TI, Barnett CP, Benninga MA, Lontis R, Goodchild L, Haslam RR et al. Mechanisms of gastro-oesophageal reflux in preterm and term infants with reflux disease. Gut 2002; 51: 475–479.
Davidson G . The role of lower esophageal sphincter function and dysmotility in gastroesophageal reflux in premature infants and in first year of life. J Pediatr Gastroenterol Nutr 2003; 37 (Suppl 1): S17–S22.
Corvaglia L, Ferlini M, Rotatori R, Paoletti V, Alessandroni R, Cocchi G et al. Starch thickening of human milk is ineffective in reducing the gastroesophageal reflux in preterm infants: a crossover study using intraluminal impedance. J Pediatr 2006; 148: 265–268.
Wenzl TG . Evaluation of gastroesophageal reflux events in children using multichannel intraluminal electrical impedance. Am J Med 2003; 115 (Suppl 3A): S161–S165.
Condino AA, Sondheimer J, Pan Z, Gralla J, Perry D, O’Connor JA . Evaluation of infantile acid and non-acid gastroesophageal reflux using combined ph monitoring and impedance measurement. J Pediatr Gastroenterol Nutr 2006; 42: 16–21.
Ramirez B, Richter JE . Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 5–20.
Vandenplas Y, Belli D, Benhamou P, Cadranel S, Cesard JP, Cucchiara S et al. A critical appraisal of current management practices for infant regurgitation recommendations of a working party. Eur J Pediatr 1997; 156: 343–357.
Rampe D, Roy ML, Dennis A, Brown AM . A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 1997; 417: 28–32.
Craig WR, Hanlon-Dearman A, Sinclair C, Taback S, Moffatt M . Metoclopramide, thickened feedings, and positioning for gastro-esophageal reflux in children under two years. The Cochran library 2008; 2: 1–34.
Ganzini L, Casey DE, Hoffman WF, McCall AL . The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993; 153: 1469–1475.
Ahmad N, Keith-Ferris J, Gooden E, Abell T . Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Phamacol 2006; 6: 571–576.
Pritchard DS, Baber N, Stephenson T . Should domperidone be used for the treatment of gastro-esophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol 2005; 59: 725–729.
Niemegeers CJ, Schellekens KH, Janssen PA . The antiemetic effects of domperidone, a novel potent gastrokinetic. Arch Int Pharmacodyn Ther 1980; 244: 130–140.
Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS . Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dispepsia and as an antiemetic. Drugs 1982; 24: 360–400.
Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H . On the pharmacokinetics of domperidone in animals and man. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet 1981; 6: 61–70.
Clara R, Van Hollebeke J, Heck E . A multicentre pilot study of parenteral and rectal administration of domperidone in the treatment of severe vomiting in children. Postgrad Med J 1979; 55: 43–44.
Barone JA . Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother 1999; 33: 429–440.
Biasini A, Alberti A . Extrapyramidal dysfunction after domperidone. Helv Pediatr Acta 1985; 40: 93–94.
Shafrir Y, Levy Y, Ben-Amitai D, Nitzan M, Steinherz R . Oculogyric crisis due to domperidone therapy. Helv Parediatric Acta 1985; 40: 95.
Rocha CM, Barbosa MM . QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol 2005; 26: 720–723.
Drolet B, Rousseau G, Daleau P, Cardinal R, Turgeon J . Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 2000; 102: 1883–1885.
Strobel CT, Byrne WJ, Ament ME, Euler AR . Correlation of esophageal lengths in children with height: application to the Tuttle test without prior esophageal manometry. J Pediatr 1979; 94: 81–84.
Tutuian R, Castell DO . Use of multichannel intraluminal impedance to document proximal esophageal and pharyngeal nonacidic reflux episodes. Am J Med 2003; 115 (Suppl 3A): S119–S123.
Wenzl TG . Investigating oesophageal reflux with the intraluminal impedance technique. J Pediatr Gastroenterol Nutr 2002; 34: 261–268.
Sifrim D, Castell D, Dent J, Kahrilas PJ . Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004; 53: 1024–1031.
Peter CS, Wiechers C, Bohnhorst B, Silny J, Poets CF . Detection of small bolus volumes using multiple intraluminal impedance in preterm infants. J Pediatr Gastroenterol Nutr 2003; 36: 381–384.
Peter CS, Sprodowski N, Ahlborn V, Wiechers C, Schlaud M, Silny J et al. Inter- and intraobserver agreement for gastroesophageal reflux detection in infants using multiple intraluminal impedance. Biol Neonate 2004; 85: 11–14.
Clark RH, Bloom BT, Spitzer AR, Gerstmann DR . Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 2006; 117: 1979–1987.
Dhillon AS, Ewer AK . Diagnosis and management of gastro-oesophageal reflux in preterm infants in neonatal intensive care units. Acta Paediatr 2004; 93: 88–93.
Carroccio A, Iacono G, Montalto G, Cavataio F, Soresi M, Notarbartolo A . Domperidone plus magnesium hydroxide and aluminum hydroxide: a valid therapy in children with gastroesophageal reflux. A double-blind randomised study versus placebo. Scand J Gastroenterol 1994; 29: 300–304.
Bines JE, Quinlan JE, Treves S, Kleinman RE, Winter HS . Efficacy of domperidone in infants and children with gastroesophageal reflux. J Pediatr Gastroenterol Nutr 1992; 14: 400–405.
De Loore I, Van Ravensteyn H, Ameryckx L . Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation. A comparison with metoclopramide. Postgrad Med J 1979; 55: 40–42.
Cresi F, de Sanctis L, Savino F, Bretto R, Testa A, Silvestro L . Relationship between gastro-oesophageal reflux and gastric activity in newborns assessed by combined intraluminal impedance, pH metry and epigastric impedance. Neurogastroenterol Motil 2006; 18: 361–368.
Acknowledgements
The authors are particularly grateful to the nursing staff for their most valuable assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
Disclosure/Conflicts of Interest
The authors declare that there is no conflict of interest.
Rights and permissions
About this article
Cite this article
Cresi, F., Marinaccio, C., Russo, M. et al. Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. J Perinatol 28, 766–770 (2008). https://doi.org/10.1038/jp.2008.81
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jp.2008.81